Progress is happening in the cell and gene therapies (CGT) space - but that does not mean that the challenges that have held it back are about to disappear.
Regulatory barriers and cost concerns continue to hamper their widespread adoption, according to the data and analytics company GlobalData, in its overview of the space.
An analysis of GlobalData’s Drug Database reveals that over the past decade, a total of 14 cell and gene therapies were approved across various therapy areas in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze